Eurofins Scientific : Director/PDMR Shareholding
MWN-AI** Summary
Eurofins Scientific SE, a leading global player in bio-analysis, has recently made noteworthy disclosures regarding transactions by Persons Discharging Managerial Responsibilities (PDMR), specifically through its controlled entity, Analytical Bioventures S.C.A., under the oversight of CEO Dr. Gilles Martin. These transactions, compliant with the European Market Abuse Regulation, highlight the ongoing activities of those in management to bolster their shareholdings, showcasing confidence in the company's future.
The notifications outline multiple acquisitions of shares within a short time frame, indicating a strategic accumulation trend. Notably, on February 10, 2026, and the subsequent days, Analytical Bioventures acquired shares at prices ranging from approximately €64.08 to €67.44 per share. A total of 1,000 shares were purchased on February 10 for about €67,439.50, followed by similar acquisitions on February 11 and 12, culminating in additional purchases and a total aggregated volume exceeding 4,000 shares across these transactions.
The significance of these transactions goes beyond numbers; they reflect a robust trust in Eurofins' ongoing growth strategies and market positioning. With a workforce of over 65,000 and a sprawling network of more than 950 laboratories globally, Eurofins maintains an extensive portfolio of over 200,000 analytical methods, catering to diverse industries, including pharmaceuticals, food, and environmental testing.
This uptrend in managerial shareholding underscores a positive outlook for investors, suggesting that key executives perceive significant potential for value creation within the company. Eurofins shares are traded on the Euronext Paris Stock Exchange, and these recent moves may draw the attention of market watchers and investors alike in anticipation of Eurofins' forthcoming performance results. For further details, stakeholders and interested parties can reach out via Eurofins' investor relations channels.
MWN-AI** Analysis
### Market Analysis: Eurofins Scientific SE
Recent notifications concerning director and managerial share acquisitions at Eurofins Scientific SE (ticker: EUFI.PA) provide insightful signals to potential investors. From February 10 to February 13, 2026, several transactions were recorded where the company controlled by Dr. Gilles Martin, Analytical Bioventures S.C.A., acquired a total of 4,000 shares at prices ranging from €64.08 to €67.44 per share. These transactions show a consistent confidence from management in the intrinsic value of the company’s stock, particularly during a period characterized by fluctuating market conditions.
The act of purchasing shares by Persons Discharging Managerial Responsibilities (PDMRs) such as Dr. Martin can be interpreted as a signal of confidence in the company’s future prospects. Given Eurofins’ position as a global leader in bio-analysis with a sprawling network, this endorsement from the top brass might suggest that the management anticipates favorable developments in revenue and profitability metrics moving forward.
On the analytics front, potential investors should pay close attention to Eurofins' growth strategies, including market expansion and technological innovations in testing methodologies. The bio-analytical sector is experiencing heightened demand, propelled by a growing emphasis on health security and environmental monitoring. Thus, increased R&D investment is likely to pay dividends in the long term.
However, investors should remain cautious about external economic variables such as inflation rates and geopolitical tensions that may impact Eurofins’ operational costs and consumer spending. Additionally, keeping an eye on the broader industry trends and how they affect Eurofins is crucial.
In summary, the recent share acquisitions suggest that the management retains strong confidence in Eurofins’ future, making it a company that deserves a spot on investors' radars. Long-term prospects appear promising, provided the firm navigates external challenges effectively.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM | |||
1. | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Analytical Bioventures S.C.A (RCS B89265) | |
2. | Reason for the notification | ||
a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin | |
b) | Initial notification / amendment | Initial | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Eurofins Scientific S.E. | |
b) | LEI | 529900JEHFM47DYY3S57 | |
4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Share | |
Identification code | ISIN: FR0014000MR3 | ||
b) | Nature of the transaction | Acquisition of shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
EUR 67.439500 | 1000 | ||
d) | Aggregated information | ||
— Aggregated volume | 1000 | ||
— Price | EUR 67,439.50 | ||
e) | Date of the transaction | 2026-02-10 | |
f) | Place of the transaction | XPAR |
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM | |||
1. | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Analytical Bioventures S.C.A (RCS B89265) | |
2. | Reason for the notification | ||
a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin | |
b) | Initial notification / amendment | Initial | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Eurofins Scientific S.E. | |
b) | LEI | 529900JEHFM47DYY3S57 | |
4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Share | |
Identification code | ISIN: FR0014000MR3 | ||
b) | Nature of the transaction | Acquisition of shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
EUR 66.212600 | 1000 | ||
d) | Aggregated information | ||
— Aggregated volume | 1000 | ||
— Price | EUR 66,212.60 | ||
e) | Date of the transaction | 2026-02-11 | |
f) | Place of the transaction | XPAR |
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM | |||
1. | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Analytical Bioventures S.C.A (RCS B89265) | |
2. | Reason for the notification | ||
a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin | |
b) | Initial notification / amendment | Initial | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Eurofins Scientific S.E. | |
b) | LEI | 529900JEHFM47DYY3S57 | |
4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Share | |
Identification code | ISIN: FR0014000MR3 | ||
b) | Nature of the transaction | Acquisition of shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
EUR 64.075500 | 2000 | ||
d) | Aggregated information | ||
— Aggregated volume | 2000 | ||
— Price | EUR 128,151.00 | ||
e) | Date of the transaction | 2026-02-12 | |
f) | Place of the transaction | XPAR |
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM | |||
1. | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Analytical Bioventures S.C.A (RCS B89265) | |
2. | Reason for the notification | ||
a) | Position / status | Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin | |
b) | Initial notification / amendment | Initial | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Eurofins Scientific S.E. | |
b) | LEI | 529900JEHFM47DYY3S57 | |
4. | Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument | Share | |
Identification code | ISIN: FR0014000MR3 | ||
b) | Nature of the transaction | Acquisition of shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
EUR 65.211300 | 1000 | ||
d) | Aggregated information | ||
— Aggregated volume | 1000 | ||
— Price | EUR 65,211.30 | ||
e) | Date of the transaction | 2026-02-13 | |
f) | Place of the transaction | XPAR |
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 65,000 staff across a network of more than 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260216529178/en/
For more information, please visit www.eurofins.com or contact:
Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
FAQ**
What insights can we gather from the recent acquisitions of shares by Analytical Bioventures S.C.A, a company controlled by Eurofins Scientific S.E. ERFSF, regarding executive confidence in the firm’s future prospects?
How might the fluctuations in share prices observed during these transactions impact investor sentiment towards Eurofins Scientific S.E. ERFSF in the short to medium term?
Considering the scale of share purchases by persons discharging managerial responsibilities at Eurofins Scientific S.E. ERFSF, what potential implications do these transactions have for corporate governance and transparency?
In light of the increasing volume of shares acquired by the management at Eurofins Scientific S.E. ERFSF, what could this indicate about the company's operational strategy and financial health moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about Eurofins Scientific S.E. (OTC: ERFSF).
NASDAQ: ERFSF
ERFSF Trading
2.31% G/L:
$75.62 Last:
520 Volume:
$74.92 Open:
